Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer

Expert Review of Molecular Diagnostics

Volumn 15, Issue 5, 2015, Pages 647-664

  Marzese, Diego M ^a   Hoon, Dave Sb ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

cancer diagnosis; DNA methylation; epigenomics; microarray; sequencing

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; CYTOSINE; GUANINE; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; COLORECTAL CANCER; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE STRUCTURE; GLIOBLASTOMA; HUMAN; MELANOMA; MOLECULAR DIAGNOSIS; NON SMALL CELL LUNG CANCER; PROSTATE CANCER; REVIEW; TECHNOLOGY; TUMOR MICROENVIRONMENT; CHROMOSOMAL MAPPING; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; NEOPLASMS; PROCEDURES;

BIOMARKERS, TUMOR; CHROMOSOME MAPPING; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS;

EID: 84928395340     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1027194     Document Type: Review

References (215)

1. Levin HL, Moran JV. Dynamic interactions between transposable elements and their hosts. Nat Rev Genet 2011;12(9):615-27
2. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-54
3. Peters J. The role of genomic imprinting in biology and disease: an expanding view. Nat Rev Genet 2014;15(8):517-30
4. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14(3):204-20
5. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462(7271):315-22 .. This study was the first whole-genome DNA methylation mapping of a human genome and describes the presence of non-cytosine-guanine (CpG) dinucleotide methylation.
6. Stevens M, Cheng JB, Li D, et al. Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res 2013; 23(9):1541-53
7. Simmen MW. Genome-scale relationships between cytosine methylation and dinucleotide abundances in animals. Genomics 2008;92(1):33-40
8. Shen L, Wu H, Diep D, et al. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 2013;153(3):692-706 . This article summarizes the newly identified functional modifications of cytosine bases in the mammalian genome.
9. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991;64(6):1123-34
10. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196(2):261-82
11. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular reprogramming. Trends Cell Biol 2010; 20(10):609-17
12. Day JJ, Sweatt JD. DNA methylation and memory formation. Nat Neurosci 2010; 13(11):1319-23
13. Deng X, Berletch JB, Nguyen DK, Disteche CM. X chromosome regulation: diverse patterns in development, tissues and disease. Nat Rev Genet 2014;15(6):367-78
14. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450, 000 CpG sites in the human genome. Epigenetics 2011;6(6): 692-702 . This article presents a comprehensive analysis of the more than 450, 000 genomic regions covered by the Human Methylation 450K BeadChip and introduces the denomination of open sea for CpG sites located more than 4 kb away from a CpG island.
15. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41(2):178-86 .. This study identified tissue- and cancer-specific differentially methylated regions located outside the traditional CpG islands, in regions denominated CpG shores.
16. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41(12):1350-3
17. Shen J, Wang S, Zhang YJ, et al. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium Human Methylation 450 BeadChips. Epigenetics 2013;8(1): 34-43
18. Marzese DM, Scolyer RA, Huynh JL, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet 2014;23(1):226-38
19. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13(7):484-92 .. This article reviews the function of DNA methylation with regard to the CpG density and gene structure.
20. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21):2042-54
21. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39(4):457-66 . This study classified gene promoters according to their CpG density and functionality.
22. Li R, Mav D, Grimm SA, et al. Fine-tuning of epigenetic regulation with respect to promoter CpG content in a cell type-specific manner. Epigenetics 2014;9(5): 747-59
23. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004;11(11):1068-75
24. Smith JF, Mahmood S, Song F, et al. Identification of DNA methylation in 3' genomic regions that are associated with upregulation of gene expression in colorectal cancer. Epigenetics 2007;2(3):161-72
25. Stroud H, Feng S, Morey Kinney S, et al. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol 2011; 12(6):R54
26. Schmidl C, Klug M, Boeld TJ, et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009;19(7): 1165-74 . This study identified a key role of DNA methylation at enhancer regions in determining cellular fate.
27. Kozlenkov A, Roussos P, Timashpolsky A, et al. Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. Nucleic Acids Res 2014;42(1):109-27
28. Liu WM, Schmid CW. Proposed roles for DNA methylation in Alu transcriptional repression and mutational inactivation. Nucleic Acids Res 1993;21(6):1351-9
29. Beck CR, Garcia-Perez JL, Badge RM, Moran JV. LINE-1 elements in structural variation and disease. Annu Rev Genomics Hum Genet 2011;12:187-215
30. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8(4):286-98
31. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59 .. This article reviews the DNA methylation misbalanced in cancer cells.
32. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11(10):726-34
33. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7(1):21-33
34. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10(26):3001-7
35. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24(2):132-8
36. Yang X, Han H, De Carvalho DD, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014;26(4):577-90
37. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216):1061-8 Available from: https://tcga-data.nci.nih.gov/ tcga/
38. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13(10): 679-92
39. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin 2010;60(6):376-92
40. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60(3):166-93
41. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
42. Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010;12(2):116-21
43. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31(32): 4085-91
44. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1):98-110
45. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5):510-22
46. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483(7390):479-83
47. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
48. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22(4):425-37 .. This study identified a new molecular classification of glioblastoma.
49. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1):9-29
50. Deschoolmeester V, Baay M, Specenier P, et al. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010; 15(7):699-731
51. Goel A, Arnold CN, Niedzwiecki D, et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003;63(7):1608-14
52. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8(12):686-700
53. Fox EJ, Leahy DT, Geraghty R, et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J Mol Diagn 2006; 8(1):68-75
54. Amatu A, Sartore-Bianchi A, Moutinho C, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013;19(8):2265-72
55. Hochhauser D, Glynne-Jones R, Potter V, et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013;12(5):809-18
56. Qi J, Zhu YQ, Huang MF, Yang D. Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World J Gastroenterol 2005;11(13):2022-5
57. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96(15):8681-6
58. Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16(1):21-33 .. This is the most update study in the classification of colorectal cancer based on DNA methylation signatures.
59. Lee S, Cho NY, Choi M, et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58(2):104-13
60. Rashid A, Shen L, Morris JS, et al. CpG island methylation in colorectal adenomas. Am J Pathol 2001;159(3):1129-35
61. Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island methylator phenotype. Mol Cell 2014;55(6):904-15
62. Sunami E, de Maat M, Vu A, et al. LINE-1 hypomethylation during primary colon cancer progression. PLoS One 2011; 6(4):e18884
63. Benard A, van de Velde CJ, Lessard L, et al. Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer 2013;109(12):3073-83
64. Umetani N, Takeuchi H, Fujimoto A, et al. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004;10(22):7475-83
65. Umetani N, Fujimoto A, Takeuchi H, et al. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma. Oncogene 2004;23(50): 8292-300
66. Umetani N, de Maat MF, Sunami E, et al. Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation. Mol Cancer Res 2006;4(5):303-9
67. Taback B, Saha S, Hoon DS. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann N Y Acad Sci 2006;1075: 197-203
68. de Maat MF, Umetani N, Sunami E, et al. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res 2007;5(5):461-71
69. Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009;101(13): 916-27
70. de Maat MF, Narita N, Benard A, et al. Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. Am J Pathol 2010;177(5): 2347-56
71. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29(1): 181-206
72. Carmona FJ, Azuara D, Berenguer-Llergo A, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila) 2013;6(7):656-65
73. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287-97
74. Benard A, Zeestraten EC, Goossens-Beumer IJ, et al. DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence. Apoptosis 2014;19(11): 1581-93
75. Yi JM, Dhir M, Van Neste L, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 2011;17(6): 1535-45
76. Simmer F, Brinkman AB, Assenov Y, et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 2012;7(12):1355-67
77. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012;22(2):271-82
78. Sipos F, Muzes G, Patai AV, et al. Genome-wide screening for understanding the role of DNA methylation in colorectal cancer. Epigenomics 2013;5(5):569-81
79. TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330-7
80. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
81. Piva R, Rimondi AP, Hanau S, et al. Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. Br J Cancer 1990;61(2):270-5
82. Sizemore ST, Sizemore GM, Booth CN, et al. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat 2014; 146(1):25-40
83. Sharma P, Stecklein SR, Kimler BF, et al. The prognostic value of promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res 2014;3(2): 1-11
84. Kagara N, Huynh KT, Kuo C, et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol 2012;181(1):257-67
85. Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 2012;109(20):7765-9
86. Shinozaki M, Hoon DS, Giuliano AE, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005;11(6):2156-62
87. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009;55(3):559-67
88. Sunami E, Shinozaki M, Sim MS, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008;10(3):R46
89. Sunami E, Vu AT, Nguyen SL, Hoon DS. Analysis of methylated circulating DNA in cancer patients' blood. Methods Mol Biol 2009;507:349-56
90. Taback B, Giuliano AE, Lai R, et al. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci 2006;1075:211-21
91. Umetani N, Mori T, Koyanagi K, et al. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 2005;24(29):4721-7
92. van Hoesel AQ, Sato Y, Elashoff DA, et al. Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer 2013;108(10):2033-8
93. van Hoesel AQ, van de Velde CJ, Kuppen PJ, et al. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat 2012;134(3):1103-14
94. van Hoesel AQ, van de Velde CJ, Kuppen PJ, et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat 2012;131(3):859-69
95. Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 2010;24(5):271-80
96. Marzese DM, Hoon DS, Chong KK, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Mol Diagn 2012;14(6):613-22
97. Rao X, Evans J, Chae H, et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene 2013;32(38):4519-28
98. Fleischer T, Frigessi A, Johnson KC, et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol 2014;15(8):435
99. Rhee JK, Kim K, Chae H, et al. Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res 2013;41(18):8464-74
100. Ambrosone CB, Young AC, Sucheston LE, et al. Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 2014;5(1):237-48
101. Ghosh S, Gu F, Wang CM, et al. Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1. Breast Cancer Res Treat 2014; 147(3):653-9
102. Johnson KC, Koestler DC, Cheng C, Christensen BC. Age-related DNA methylation in normal breast tissue and its relationship with invasive breast tumor methylation. Epigenetics 2014;9(2): 268-75
103. Lindqvist BM, Wingren S, Motlagh PB, Nilsson TK. Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics 2014;9(8):1149-62
104. Wang F, Yang Y, Fu Z, et al. Differential DNA methylation status between breast carcinomatous and normal tissues. Biomed Pharmacother 2014;68(6):699-707
105. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418):61-70 .. The Cancer Genome Atlas study identified five breast cancer DNA methylation subtypes.
106. Roessler J, Ammerpohl O, Gutwein J, et al. The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. Epigenomics 2014;1-13
107. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63
108. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355(1):51-65
109. Spugnardi M, Tommasi S, Dammann R, et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63(7):1639-43
110. Hoon DS, Spugnardi M, Kuo C, et al. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23(22):4014-22
111. Mori T, Kim J, Yamano T, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005;65(5):1800-7
112. Mori T, O'Day SJ, Umetani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23(36):9351-8
113. Koyanagi K, Mori T, O'Day SJ, et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006;66(12):6111-17
114. Mori T, Martinez SR, O'Day SJ, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 2006; 66(13):6692-8
115. Kitago M, Martinez SR, Nakamura T, et al. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009;15(9):2988-94
116. Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011;6(3): 388-94
117. Hoshimoto S, Kuo CT, Chong KK, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 2012;132(6):1689-97
118. Huynh KT, Takei Y, Kuo C, et al. Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. Br J Dermatol 2012; 166(6):1319-26
119. Sato Y, Marzese DM, Ohta K, et al. Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma. Epigenetics 2013;8(10):1043-52
120. Fratta E, Sigalotti L, Covre A, et al. Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy 2013;5(10):1103-16
121. Greenberg ES, Chong KK, Huynh KT, et al. Epigenetic biomarkers in skin cancer. Cancer Lett 2014;342(2):170-7
122. Conway K, Edmiston SN, Khondker ZS, et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 2011;24(2):352-60
123. Sigalotti L, Covre A, Fratta E, et al. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med 2012;10:185
124. Marzese DM, Huynh JL, Kawas NP, Hoon DSB. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Genom Data 2014;2:150-2
125. Marzese DM, Scolyer RA, Roque M, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro Oncol 2014; 16(11):1499-509
126. Marzese DM, Liu M, Huynh JL, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 2014;28(1):82-93
127. Tanemura A, Terando AM, Sim MS, et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009;15(5):1801-7
128. Hou P, Liu D, Dong J, Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell cycle 2012;11(2): 286-95
129. Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer. Oncologist 2013;18(6):707-16
130. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150(6):1121-34
131. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31(23):2895-902
132. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013;31(32):4140-7
133. TCGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511(7511):543-50
134. TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25
135. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-78
136. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91(24):11733-7
137. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004;46(6): 698-708
138. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9(7):2673-7
139. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 2001;945:51-8
140. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60(6):1131-5
141. Wu T, Giovannucci E, Welge J, et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 2011;105(1):65-73
142. Wagner I, Capesius I. Determination of 5-methylcytosine from plant DNA by high-performance liquid chromatography. Biochim Biophys Acta 1981;654(1):52-6
143. Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999;85(1):112-18
144. Chen ML, Shen F, Huang W, et al. Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. Clin Chem 2013;59(5): 824-32
145. Poloni A, Goteri G, Zizzi A, et al. Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. Eur J Haematol 2013;91(3): 219-27
146. Riganti C, Salaroglio IC, Caldera V, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/ glycogen synthase-3 kinase/beta-catenin pathway. Neuro Oncol 2013;15(11): 1502-17
147. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93(18): 9821-6
148. Lo YM, Wong IH, Zhang J, et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 1999;59(16):3899-903
149. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28(8):E32
150. Colella S, Shen L, Baggerly KA, et al. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35(1): 146-50
151. Clark SJ, Statham A, Stirzaker C, et al. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006;1(5):2353-64
152. Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol 2015; 10(3):509-17
153. Hu WS, Fanning TG, Cardiff RD. Mouse mammary tumor virus: specific methylation patterns of proviral DNA in normal mouse tissues. J Virol 1984;49(1):66-71
154. Khulan B, Thompson RF, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006;16(8):1046-55
155. Hatada I, Fukasawa M, Kimura M, et al. Genome-wide profiling of promoter methylation in human. Oncogene 2006; 25(21):3059-64
156. Lee EJ, Luo J, Wilson JM, Shi H. Analyzing the cancer methylome through targeted bisulfite sequencing. Cancer Lett 2013;340(2):171-8
157. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37(8):853-62 .. This review introduced the methylated DNA immunoprecipitation technique. In this first publication, methylated DNA immunoprecipitation was coupled with a microarray.
158. Flanagan JM, Cocciardi S, Waddell N, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet 2010; 86(3):420-33
159. Ruike Y, Imanaka Y, Sato F, et al. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 2010;11:137
160. Lendvai A, Johannes F, Grimm C, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics 2012;7(11):1268-78
161. Zhang B, Xing X, Li J, et al. Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. BMC Genomics 2014;15(1):868
162. Yalcin A, Kreutz C, Pfeifer D, et al. MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells. Leuk Res 2013;37(1):102-11
163. Gloss BS, Patterson KI, Barton CA, et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 2012;318(1):76-85
164. Morris MR, Ricketts CJ, Gentle D, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011;30(12):1390-401
165. Cheung HH, Lee TL, Davis AJ, et al. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer 2010;102(2):419-27
166. Brinkman AB, Simmer F, Ma K, et al. Whole-genome DNA methylation profiling using MethylCap-seq. Methods 2010;52(3): 232-6
167. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010;38(2):391-9
168. Bock C, Tomazou EM, Brinkman AB, et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 2010;28(10): 1106-14
169. Zhao Y, Guo S, Sun J, et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 2012;7(4):e35175
170. Niederwieser C, Kohlschmidt J, Volinia S, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 2015;29(3): 567-75
171. Carvalho RH, Haberle V, Hou J, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin 2012;5(1):9
172. Carvalho RH, Hou J, Haberle V, et al. Genome-wide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas. J Thorac Oncol 2013;8(5):562-73
173. Yu W, Jin C, Lou X, et al. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One 2011;6(12):e29450
174. Huang RL, Gu F, Kirma NB, et al. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics 2013;8(6):624-34
175. Sharpe K, Stewart GD, Mackay A, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 2013;19(24): 6924-34
176. Jorgensen HF, Ben-Porath I, Bird AP. Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol 2004;24(8):3387-95
177. Bianchi C, Zangi R. Molecular dynamics study of the recognition of dimethylated CpG sites by MBD1 protein. J Chem Inf Model 2015. [Epub ahead of print]
178. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17(1): 13-27
179. Irizarry RA, Ladd-Acosta C, Carvalho B, et al. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res 2008;18(5):780-90
180. Busche S, Ge B, Vidal R, et al. Integration of high-resolution methylome and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia. Cancer Res 2013;73(14):4323-36
181. Naumov VA, Generozov EV, Zaharjevskaya NB, et al. Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics 2013;8(9):921-34
182. Cheng Y, Yan Z, Liu Y, et al. Analysis of DNA methylation patterns associated with the gastric cancer genome. Oncol Lett 2014; 7(4):1021-6
183. Gasperov NM, Farkas SA, Nilsson TK, Grce M. Epigenetic activation of immune genes in cervical cancer. Immunol Lett 2014;162(2 Pt B):256-7
184. Karlsson A, Jonsson M, Lauss M, et al. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuorendocrine and four adenocarcinoma epitypes associated with patient outcome. Clin Cancer Res 2014;20(23):6127-40
185. Chen YA, Lemire M, Choufani S, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 2013;8(2):203-9
186. Heyn H, Li N, Ferreira HJ, et al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci USA 2012;109(26):10522-7
187. Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011;43(8):768-75
188. Berman BP, Weisenberger DJ, Aman JF, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012;44(1):40-6
189. Meissner A, Gnirke A, Bell GW, et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res 2005;33(18):5868-77 .. This review introduced the adaptation of whole-genome bisulfite sequencing named reduced representation bisulfite sequencing.
190. Diep D, Plongthongkum N, Gore A, et al. Library-free methylation sequencing with bisulfite padlock probes. Nat Methods 2012;9(3):270-2
191. Wang Q, Gu L, Adey A, et al. Tagmentation-based whole-genome bisulfite sequencing. Nat Protoc 2013;8(10):2022-32
192. Li S, Chowdhury R, Liu F, et al. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res 2014;20(22):5808-22
193. Pei L, Choi JH, Liu J, et al. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics 2012;7(6):567-78
194. Ashktorab H, Daremipouran M, Goel A, et al. DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics 2014;9(4):503-12
195. Booth MJ, Ost TW, Beraldi D, et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat Protoc 2013; 8(10):1841-51 . Describes an adaptation of bisulfite sequencing to distinguish 5-methylcytosine from 5-hydroxymethyl-cytocine by inducing the oxidation of 5-hydroxymethylcytocine.
196. Stewart SK, Morris TJ, Guilhamon P, et al. oxBS-450K: a method for analysing hydroxymethylation using 450K BeadChips. Methods 2015;72:9-15
197. Yu M, Hon GC, Szulwach KE, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 2012;149(6):1368-80
198. Flusberg BA, Webster DR, Lee JH, et al. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods 2010;7(6):461-5 . Introduces the third-generation of sequencing technologies to study DNA methylation maps.
199. Hsiung DT, Marsit CJ, Houseman EA, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007;16(1): 108-14
200. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008;54(2):414-23
201. Chimonidou M, Strati A, Tzitzira A, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57(8): 1169-77
202. Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007;13(4):1179-85
203. Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007; 13(24):7296-304
204. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91(4):332-9
205. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95(20):11891-6
206. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009;69(11):4691-9
207. Jeronimo C, Costa I, Martins MC, et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003; 9(9):3413-17
208. Pellise M, Castells A, Gines A, et al. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonographyguided fine-needle aspiration biopsy. Clin Cancer Res 2004;10(13):4444-9
209. Ma Y, Wang X, Jin H. Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci 2013;14(5):10307-31 .. Reviews the utility of DNA methylation as a biomarker in body fluids.
210. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61(8):3225-9
211. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502(7471):333-9
212. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499(7457):214-18
213. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463): 415-21
214. Brocks D, Assenov Y, Minner S, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 2014;8(3):798-806
215. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10): 883-92